Novel thermoresponsive polymers

Reference number 8847

Sectors: Pharmaceuticals

Industries: Pharmaceuticals

Technology overview

Amphiphilic copolymers (i.e. polymers that contain both hydrophilic and hydrophobic components) have a vast variety of applications, such as drug delivery, tissue engineering, emulsifiers and demulsifiers. A well-known amphiphilic family of polymers is the Pluronic family® which have been used as stabilisers, defoaming agents, binders, and gelling agents in cosmetics, medicine agriculture, dental bleaching and the textile and food industries. However, in some cases, the gelling and rheological properties of the commercially available polymers are not optimised. Some of the polymers (Pluronic® family) can form non-stable gels and fail the clinical trials after body injection in the application of replacing damage issue.

Thus, a new novel block copolymer comprising at least three blocks using a commercial manufacturing method called Group Transfer Polymerisation (GTP) has been invented by researchers at Imperial College London. The advantage these polymers, over current commercial alternatives, is that they play a critical role in influencing the rheological and thermogelling properties of polymer solutions and the formation of gels at lower concentrations. In order to satisfy customers’ needs, a range of polymers could be obtained by varying the polymer characteristics independently, including: molar mass, composition and architecture.


  • Easy scale-up and cheap preparation method
  • Excellent rheological and thermogelling properties
  • Cost-effective, low production cost, enable form gel at lower concentrations than any other synthetic polymer in the commercial market
  • “Tailored” properties: Molar mass, composition and architecture. High flexibility of changing properties to satisfy customers’ need

Intellectual Property

Polymers: International application number PCT/GB2019/052686


Dr Theoni K. Georgiou

Reader in Polymer Chemistry
Faculty of Engineering, Department of Materials

Visit personal site
Dr Anna Constantinou

Research Associate

Visit personal site

Contact us about this technology


Dr Valeska Gonzalez

Industry Partnerships and Commercialisation Executive, Engineering

Dr Valeska Gonzalez is Industry Partnerships and Commercialisation Executive for the Faculty of Engineering at Imperial College London

Contact Valeska

+44 (0)20 7594 6893

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.